INTRODUCTION
Viruses are widely used tools for therapeutic gene delivery of many critical diseases. Although a few hurdles have been overcome to achieve practical success, one promising group of anticancer agents is the oncolytic viruses (Cattaneo et al., 2008) .
Among oncolytic viruses, oncolytic adenovirus (Ad) is a widely used anti-tumor activity tool for many different tumor types (Toth et al., 2010) . A number of preclinical and clinical studies have used oncolytic Ad with encouraging results (Kumar et al., 2008) . Of note, an in vivo evaluation of an adenoviral gene delivery was limited due to the lack of a suitable animal model. Infection with Ad is species-specific, and the replication ability of human-originating Ad is much lower than that in laboratory animals. Development of a new experimental animal model is needed prior to testing larger animals and conducting clinical trials. Zebrafish (Danio rerio) are a good model to test gene delivery efficiency because a zebrafish homologue of the coxsackievirus and Ad receptor protein has been identified (Petrella et al., 2002) . Zebrafish can serve as a chemical treatment cancer model or through transplantation of mammalian cells (Feitsma and Cuppen, 2008) .
Ad has immunogenic properties and induces inflammatory activity (Yang et al., 1994) . Additionally, the stability and efficiency of Ad is weakened at increased temperatures. To overcome these disadvantages, development of an Ad vehicle may help protect the stability of Ad. We recently reported that the efficiency of gene delivery is significantly enhanced using a proteoliposome (PL) containing apolipoprotein A-I in various cell and zebrafish models (Park et al., 2010) . We also showed that human-originating Ad replicates in zebrafish. Adult zebrafish can be infected with Ad, particularly with PL containing apoA-I. A PL containing V156K (V156K-PL-Ad) has near twofold enhanced GFP expression than a PL containing a wildtype apoA-I (WT-PL-Ad), raising the possibility that Ad can be formulated in PL as a novel tool for targeted gene delivery, which would have a variety of therapeutic applications (Park et al., 2010) . The formulation of Ad in PL greatly enhances the efficiency of adenoviral gene delivery in various cell and zebrafish models. Additionally, the anti-inflammatory and antioxidant activities of apoA-I administered in this fashion could be used to treat cancer.
In the current study, we assessed the tumor removal effect of oncolytic Ad alone or Ad in WT-PL-Ad or V156K-PL-Ad using tumor-bearing zebrafish.
MATERIALS AND METHODS

Materials
Dimyristoyl phosphatidylcholine (DMPC; #121518, 1 g) and cholesterol (# C8667) were purchased from Avanti Polar Lipids, Inc. (USA) and Sigma (USA), respectively.
Purification of WT and V156K apoA-I WT and V156K apoA-I were expressed in an E. coli expression system and then purified using Ni 2+ -column chromatography as described previously (Cho et al., 2006; Han et al., 2005) . Protein purity was assessed by 20% sodium dodecyl sulfate-poly acrylamide gel electrophoresis using a Pharmacia Phast System (Uppsala, Sweden). The functional and structural characterization of the apoA-I in lipid-free state and lipid-bound state was carried out according to our previous report (Cho, 2009a; Park and Cho, 2011) Generation of oncolytic Ad regulated by the recombinant HRE-AFP promoter To construct oncolytic Ads targeting hepatocellular carcinoma, the recombinant AFP promoter excised from pBlueScriptII (+) was sub-cloned into phAFP-d19, pre-digested with SalI/XhoI, and the six copies of HRE, which were digested with SalI/XhoI from pTeasy/HRE 6 , were inserted into an E1 shuttle vector containing the modified AFP promoter. The resulting shuttle vector (pHa2bmd19) was linearized with XmnI, then co-transformed into E. coli BJ5183 together with the BstBI-digested adenoviral plasmid (vmdl324BstBI) for homologous recombination.
The oncolytic Ad (Ha2bm-d19) was propagated in 293A cells, purified by the cesium chloride density purification method, dissolved in storage solution (10 mM Tris, 4% sucrose, and 2 mM MgCl 2 ), and stored at -80°C before use according to a standard protocol (Hitt et al., 1994) . Viral particle numbers were calculated from measurements of optical density at 260 nm, in which 1 absorbance unit was equivalent to 1 × 10 12 viral particles per ml.
Synthesis of a PL with oncolytic Ad PL containing DMPC, free cholesterol (FC), and apoA-I were synthesized by sonication using an initial molar ratio of DMPC: FC: apoA-I of 200:9:1. During synthesis, 10 µl of the oncolytic Ad stock solution (final concentration, 1.2 × 10 9 particles/µl of PL) was added to the PL, which was incubated at room temperature for 24 h to allow association of the PL and Ad, as described previously (Park et al., 2010) .
Zebrafish and tumor induction
Zebrafish and zebrafish embryos were maintained according to standard protocols (Nusslein-Volhard, 2002) . Procedures involving zebrafish were approved by the Committee of Animal Care and Use of Yeungnam University (Korea). The zebrafish larvae and embryos were maintained in a system cage and 6-well plates at 28°C during treatment under a 14:10 h light: dark cycle. Tetrabit were used as the basal diet, supplemented with Atremia salina nauplii.
Primary tumors were induced in 11-week-old zebrafish by continuous immersion in N-nitrosodiethylamine (DEN) solution (100 ppm) for 8 weeks, as described previously (Mizgireuv and Revskoy, 2006) . Thirty zebrafish were maintained in a 10-L glass tank equipped with a mechanical filter and automatic heater during the DEN exposure. After the exposure, the fish were transferred to a 20-L tank and were observed for up to 9 months.
Zebrafish microinjection WT-PL-Ad or V156K-PL-Ad were individually microinjected using a pneumatic picopump (PV820; World Precision Instruments, USA) equipped with a magnetic manipulator (MM33; Kantec, USA) with a pulled microcapillary pipette-using device (PC-10; Narishigen, Japan) into 36-week-old zebrafish, which had grossly visible neoplasms located on the ventral region. Injections were performed at the same site on the tumor with a total of 100 nl of V156K-PL-Ad or WT-PL-Ad (5.7 × 10 6 virus particle, 36 ng of apoA-I) to minimize bias as previously reported by Cho group (Park and Cho, 2011). Filter-sterilized solutions with the same number of Ad in each vehicle were injected into zebrafish after anesthetization with tricaine methane sulfonate (Sigma A5040, final concentration, 0.002%).
After injection, live zebrafish were observed under a stereomicroscope (Motic SMZ 168, Hong Kong, China) and photographed using a motic cam 2300 CCD camera.
Histological analysis
After three injections per day within a 24-h interval for up to 72 hours, all zebrafish were sacrificed, fixed in 4% solution of paraformaldehyde, and microsectioned with a cryotome (MICROM, HM500; Germany). The tumor site in the ventral region was sectioned longitudinally from head-to-tail and stained with hematoxyin and eosin. In order to compare extent of DNA replication in the tumor site, we employed fluorescent dye using DAPI as previously described (Kapuscinski, 1990) . Photographs of the slides were obtained using a Nikon Eclipse TE2000 microscope (Japan) at 600× magnification.
Reactive oxygen species (ROS) imaging
After treatment of zebrafish with Ad or PL-Ad, the increased ROS and inflammatory response in the injected area were imaged using dihydroethidium (DHE, Sigma cat # 37291) as described previously (Owusu-Ansah et al., 2008) . The stained image of tumor site was obtained by fluorescence observation (Ex = 588 nm and Em = 605 nm) using a Nikon Eclipse TE2000 microscope. Quantification of the fluorescence area in the injected area was carried out via computer-assisted morphometry using Image Proplus software (version 4.5.1.22; Media Cybernetics, USA).
Anti-tumor effects of Ad-PL complexes in the liver cancer xenograft model To establish the Hep3B tumor xenograft model, 1 × 10 7 cells were subcutaneously injected into the abdomens of 7-week-old male athymic nu/nu mice (Orientbio Inc, Korea). When tumor volume reached about 150 mm 3 , the mice were divided into four separate groups (n = 6 per group) and injected intratumorally with 30 µl PBS or 3 × 10 9 VP of Ha2bm-d19, Ha2bm-d19:V156K, or Ha2bm-d19:WT in 30 µl of PBS three times every other day. Tumor growth was measured with calipers every 2 days, and tumor volume was calculated (volume = 0.523 × length × width
